Diabetes, one of the most widespread chronic diseases globally, requires a multidisciplinary approach and access to up-to-date information to ensure effective management. In this context, the platform Diabeta provides information resources on diabetes.
GLP-1: Role and benefits
GLP-1 receptor-based therapies have become a topic of great interest on Diabeta due to their remarkable effectiveness in controlling blood sugar and the additional benefits for patients. GLP-1 is an endogenous hormone that regulates blood glucose levels. Research has led to the development of GLP-1 analogues, which improve this natural function.
GLP-1 benefits for patients:
- Higher glycemic control: GLP-1 analogues stimulate insulin secretion and reduce glucagon production only when blood sugar is high, which minimizes the risk of hypoglycaemia.
- Weight loss: A unique effect of these drugs is the promotion of weight loss, a crucial factor in controlling type 2 diabetes, especially in obese patients.
- Convenient administration: Modern therapies include weekly options, increasing patients’ adherence to treatment.
How Diabetes Supports Physicians in Using GLP-1
For physicians interested in integrating GLP-1 analogues into treatment regimens, Diabeta it is an indispensable resource. The platform provides up-to-date information from SPCs and treatment guides. Diabetes offers indications and contraindications of GLP-1 analogues, as well as about how to integrate them in personalized treatments.
The impact of the platform on patients
Although Diabeta it is dedicated to doctors, the benefits inevitably extend to patients. Doctors who use this platform are better prepared to offer personalized treatments and explain modern therapeutic options. In addition, continuous information reduces the risk of complications and increases the quality of life of patients.
Diabeta was developed by a Romanian company, Apollo Technologies, specialized in creating professional applications based on artificial intelligence. The application is made available to doctors in professional medical communities administered by People and Companies, with the support of the partners Novo Nordisk, Boehringer Ingelheim and Medtronic.
